to other proteins (reviewed in ref. 15 ).
The proteins encoded by BRCA1 and ATM may be
Generation of a mouse model of BRCA1-induced neoplasia important in DNA repair and maintenance of genomic has been attempted through gene targeting of the mouse integrity. Women heterozygous for a mutation in BRCA1 homolog of BRCA1 (1, 3, 16, 17) . Such mutations are embryonic have an increased incidence of breast cancer. Some evidence lethals when homozygous, and heterozygous animals are not also suggests that female carriers of ATM mutations may obviously susceptible to mammary tumor development. One be susceptible to breast cancer. However, mice carrying explanation for the lack of mammary tumors in Brca1 ϩ/-mice one mutant allele of Brca1 or Atm are not highly susceptible is that further mutational events are required and the relatively to breast cancer. We proposed that heterozygosity for a short lifespan of the laboratory mouse does not allow enough mutant allele of Brca1 or Atm may confer a decreased time for these events to occur. This idea is supported by the ability to repair DNA damage. Such a defect might lead to observation that mice carrying both a conditional allele and a heightened sensitivity to tumor development in susceptible null allele of Brca1 develop mammary tumors following animal models. Therefore, mice predispose to mammary mammary gland-specific deletion of the conditional allele (18). tumor development might show an increased susceptibility However, tumors developed in a small number of mice only if they also carry an Atm or Brca1 mutation. C57BL/6J (B6) after a long latency period. Thus, loss of Brca1 function is Min/⍣ mice are predisposed to mammary and intestinal not sufficient for tumor development and further events are tumors and exposure to the point mutagen ethylnitrosourea required. Introduction of a p53 mutation increases mammary (ENU) markedly increases mammary tumor multiplicity tumor multiplicity in the conditional mutants, as well as in and incidence. To test our hypothesis, B6.Min/⍣ male mice mice heterozygous for Brca1 mutation (19). Tumors lacking were crossed with 129S6/SvEvTac females heterozygous for BRCA1 frequently have multiple genetic alterations. These a mutant allele of either Brca1 or Atm. Female progeny observations led to the hypothesis that loss of BRCA1 would from each cross were treated with ENU and followed for allow these genetic alterations to accumulate and that loss of tumor development. Only Min/⍣ F1 females developed p53 function would allow the cells to escape apoptosis and mammary tumors and heterozygosity for a mutant Brca1 continue to proliferate and accumulate mutations. Tumors or Atm allele had no effect on mammary or intestinal could arise as a result of the accumulated loss of growth tumor incidence and multiplicity. These results suggest that heterozygosity for a mutation in Brca1 or Atm does not control through loss or alteration of tumor suppressor genes. affect Min-induced tumorigenesis in mice under these Homozygosity for mutations in ATM results in the disorder conditions. Additionally, exposure to a somatic point ataxia telangiectasia (AT) (7). AT patients are extremely mutagen does not increase tumor development in mice sensitive to the effects of ionizing radiation and are highly carrying Brca1 or Atm mutations.
susceptible to malignancies, particularly lymphomas. Cells from AT patients also exhibit hypersensitivity to ionizing radiation, genomic instability and defects in cell cycle checkpoint responses (20-22). The clinical and cellular manifestaThe identification of genetic alterations that confer an increased tions of the disease are consistent with a defect in DNA risk of breast cancer is required for effective treatment and double-strand break repair or maintenance of genomic stability. prevention of the disease. Defects in genes that control the ATM has been shown to play an important role in the activation cellular response to DNA damage might influence cancer of proteins, such as BRCA1, that are involved in the repair of development by causing an elevated mutation rate or increased DNA damage. Thus, cells that lack ATM function cannot genomic instability. The gene products encoded by the BRCA1 respond appropriately to DNA damage and would continue to tumor suppressor gene (1-6) and the ATM gene (7-10) have proliferate, resulting in mutations or alterations in DNA.
Epidemiological studies involving families of AT patients
Abbreviations: AT, ataxia telangiectasia; ENU, ethylnitrosourea.
have suggested that females who carry one mutant allele damage or maintain genomic integrity, then we would expect an increased mammary tumor incidence in Min/ϩ mice carryof ATM may be at an increased risk of developing breast cancer (12,23). Interestingly, there is some evidence that early ing either mutation compared with mice carrying the Min mutation alone. exposure to irradiation may increase the risk of mammary tumors in ATM heterozygotes. However, other studies do not
To test whether heterozygosity for a mutation at Brca1 or Atm increased mammary tumor susceptibility in B6.Min/ϩ support an elevated risk of breast cancer in ATM mutation carriers (24-26). Further, there is speculation that ATM may mice, we crossed 129S6/SvEvTac females heterozygous for Brca1 ∆11/ϩ (Brca1 ϩ/-) (D.Larson and A.Wynshaw-Boris, act as a low penetrance susceptibility gene (27) . In this case, ATM mutations might predispose women to breast cancer only unpublished results) or Atm ins5790neo (Atm ϩ/-) (8) with C57BL6/ J (B6) Min/ϩ males. The Brca1 mutant mice have similar in concert with other mutations. It would be useful to develop an animal model that could be used to explore some of the phenotypes to several published mutant Brca1 alleles. The targeted mutation was generated by replacement of 1.5 kb of questions raised by these human studies.
Atm-deficient mice have been generated by gene targeting exon 11 with a PGK-neo selectable marker. These mice have no detectable heterozygous phenotype and homozygous (8,9,28). Homozygous mutant animals generally recapitulate most of the features of human AT. Heterozygous mutant mutants die between E6.5 and E8.5 (D.Larson and A.Wynshaw-Boris, unpublished results). All mice were promice are phenotypically normal and are not susceptible to spontaneous malignancies. However, when exposed to subduced and maintained at the University of Wisconsin Medical School Research Animal Facility. All female progeny were lethal doses of ionizing radiation, Atm ϩ/-mice show reduced survival and premature graying as compared with wild-type genotyped for the Min mutation as described (33). Genotyping for the Brca1 mutant allele was performed by PCR using a siblings (29). These results suggest that Atm mutations may be haploinsufficient when the mice are stressed by exposure three primer set with a common 3Ј primer (5Ј-TGC ATT TGC AGT TGA CCC) and one wild-type allele-specific 5Ј primer to irradiation. This observation also supports a role for ATM in the response of the cell to DNA damage.
(5Ј-TAA TGA GGT GAT CAT GAT A) and one targeted allele-specific 5Ј primer (5Ј-TAA AGC GCA TGC TCC AG). We investigated whether heterozygosity for an Atm or Brca1 mutation would increase breast cancer susceptibility by A three primer set was also used to genotype mice for the Atm mutant allele (5Ј-GAC TTC TGT CAG ATG TTG CTG reducing the ability to maintain genomic stability or repair DNA damage, possibly resulting in an increased mutation rate.
CC is the common primer, 5Ј-CGA ATT TGC AGG AGT TGC TGA G is specific for the wild-type allele and 5Ј-GGG Since mice carrying one mutant allele of Brca1 or Atm do not develop spontaneous mammary tumors, we tested our TGG GAT TAG ATA AAT GCC TG is specific for the targeted allele). The cycling conditions were 2 min at 94°C, 30 cycles hypothesis using a mouse model that is sensitive to mammary tumor development. The Min mouse carries a dominant mutaof 20 s at 94°C, 30 s at 50°C and 1 min at 72°C, followed by 5 min at 72°C. Brca1 PCR products were visualized on 4% tion in the Apc tumor suppressor gene and is predisposed to intestinal, desmoid and mammary tumors (30, 31) . After agarose gels and Atm PCR products were visualized on 2% agarose gels. treatment with the alkylating agent ethylnitrosourea (ENU), mammary tumor incidence markedly increases in Apc Min /ϩ Mice were injected i.p. with 50 mg ENU/kg body wt when between 35 and 45 days of age (32), then palpated weekly for (Min/ϩ) female mice (32) . Thus, if heterozygosity for a Brca1 or Atm mutation reduces the capacity of a cell to repair DNA tumors. Mice were killed when moribund or 100 days after formalin. Intestinal tumors were also counted as described (30) . tumors was different for the Brca1 ϩ/-Min/ϩ mice as compared 6. Zhong,Q., Chen,C.F., Li,S., Chen,Y., Wang,C.C., Xiao,J., Chen,P.L., with the Brca1 ϩ/ϩ Min/ϩ mice (Table I) with the mammary tumors, the number of intestinal tumors 66, S177-S182.
was not affected by heterozygosity for a mutation at Brca1 or 
